Skip Navigation

European Heart Journal 1996 17(4):550-556;
Copyright © 1996 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Theodorakis, G. N.
Right arrow Articles by Kremastinos, D. TH.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Theodorakis, G. N.
Right arrow Articles by Kremastinos, D. TH.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 The European Society of Cardiology

Clinical, adrenergic and heart endocrine measures in chronic atrial fibrillation as predictors of conversion and maintenance of sinus rhythm after direct current cardioversion

G. N. Theodorakis, M. Markianos, C. K. Kouroubetsis, E. G. Livanis, I. A. Paraskevaidis and D. TH. Kremastinos

Cardiac Department of the Athens General and Eginition Hospital, Athens University Medical School Athens, Greece

Received 17 July 1995; accepted 7 August 1995.

Correspondence: George N. Theodorakis, MD, Onassis Cardiac Surgery Center, 356, Sygrou Aye, GR-74 Athens, Greece

Abstract

The aim of this study was to evaluate clinical, adrenergic and endocrine factors that could predict sinus rhythm maintenance after direct current cardioversion in chronic atrial fibrillation.

Nineteen patients with chronic non-rheumatic atrial fibrillation (mean duration 6±5 months) were studied. They were exercised 24 h before cardioversion at maximum effort with the Naughton protocol. Heart rate and blood pressure at rest and exercise were recorded and blood samples were taken for the assessment of adrenergic activity, by measuring cyclic adenosine monophosphate, heart endocrine function, atrial natriuretic peptide and its second messenger, cyclic guanosine monophosphate. Fifteen of the 19 patients were initially converted to sinus rhythm (eight patients with external and seven patients with internal DC shocks). After 3 months eight patients remained in sinus rhythm and 11 had relapsed, most of them within the first month. On exercise the chronotropic response was lower in the group who remained in sinus rhythm than in the group in atrial fibrillation (peak heart rate 147±11 beats.min–1 vs 165±24 beats.min–1 p=0·02). During exercise, the systolic blood pressure in the sinus group reached higher values than in the group who relapsed (192±17 mmHg vs 176±18 mmHg, p=0·03). Cyclic adenosine monophosphate increased significantly from rest to peak exercise in the sinus rhythm group (from 23±9 pmol.ml–1 to 31±15 mol.ml–1, p=0·02) while it remained unchanged in the atrial fibrillation group (25±10 pmol.ml–1 to 24±8 pmol.ml–1, p=0·02). For all 19 patients the differ ence in cyclic adenosine monophosphate between rest and exercise was negatively correlated with maximum heart rate (r=0·58, p=0·009). Atrial natriuretic peptide increased from rest to peak exercise in the sinus rhythm group (from l29±58 fmol.ml–1 to 140±66fmol.ml–1 while it remained unchanged in the group in which atrial fibrillation persisted or recurred (from 112±58 fmol.ml–1 to 111±53 fmol.ml–1 p=0· A significant correlation between atrial natriuretic peptide and cyclic guanosine monophosphate levels at exercise before cardioversion was found for the sinus rhythm group only (r=0·76, p=0·02).

In patients with non-rheumatic chronic atrial fibrillation evaluation of clinical parameters such as heart rate and blood pressure changes during maximal exercise can be useful in the choice of suitable therapy. An inadequate increase in plasma cyclic-adenosine monophosphate and atrial natriuretic peptide on exercise could predict patients with more severe underlying disease, where cardioversion should not be recommended.

Key Words: Atrial fibrillation prognosis • atrial natriuretic peptide • cyclic guanosine monophosphate • cyclic adenosine monophosphate


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EuropaceHome page
M. P. van den Berg, I. C. van Gelder, and D. J. van Veldhuisen
Depletion of atrial natriuretic peptide during longstanding atrial fibrillation
Europace, January 1, 2004; 6(5): 433 - 437.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
F. Yoshihara, T. Nishikimi, Y. Sasako, J. Hino, J. Kobayashi, K. Minatoya, K. Bando, Y. Kosakai, T. Horio, S.-i. Suga, et al.
Plasma atrial natriuretic peptide concentration inversely correlates with left atrial collagen volume fraction in patients with atrial fibrillation: Plasma ANP as a possible biochemical marker to predict the outcome of the maze procedure
J. Am. Coll. Cardiol., January 16, 2002; 39(2): 288 - 294.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. Rossi, M. Enriquez-Sarano, J. C. Burnett Jr., A. Lerman, M. D. Abel, and J. B. Seward
Natriuretic peptide levels in atrial fibrillation: A prospective hormonal and Doppler-echocardiographic study
J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1256 - 1262.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.